Mehrdad Mahdad, MD
Neurology · Fountain Valley, CANPI 1225092190
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,920 and has fallen 69.2% since, to $591 in 2025.
Across 324 payments — averaging $25.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Biogen$950
- Supernus Pharmaceuticals, Inc.$636
- Lilly USA, LLC$593
- Neurocrine Biosciences, Inc.$507
- plus $3K from 18 others
Across 277 payments — averaging $2441.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$471K
- Avanir Pharmaceuticals, Inc.$134K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$38K
- Biogen$33K
What the payments were for
- Speaking & faculty fees$130%
- Travel & lodging$90%
- Food & beverage$7,93995%
- Education$4155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $1,321 |
| AbbVie(2 entities) | 64 | $1,180 |
| Biogen | 23 | $950 |
| Supernus Pharmaceuticals, Inc. | 50 | $636 |
| Lilly USA, LLC | 10 | $593 |
| Neurocrine Biosciences, Inc. | 4 | $507 |
| Eisai Inc. | 17 | $494 |
| Novartis | 52 | $371 |
| AstraZeneca(2 entities) | 4 | $332 |
| Acorda Therapeutics, Inc | 5 | $253 |
| Johnson & Johnson(2 entities) | 4 | $241 |
| EMD Serono, Inc. | 3 | $234 |
| Sunovion Pharmaceuticals Inc. | 10 | $198 |
| Biohaven Pharmaceuticals, Inc. | 7 | $157 |
| Genentech USA, Inc. | 3 | $148 |
| SK Life Science, Inc. | 7 | $138 |
| Sanofi | 1 | $125 |
| Amgen | 1 | $122 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $120 |
| TG Therapeutics, Inc. | 1 | $99 |
| Acadia Pharmaceuticals Inc | 5 | $81 |
| UCB, Inc. | 2 | $47 |
| MDD US Operations, LLC | 1 | $22 |
| Travere Therapeutics, Inc. | 3 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,376 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $78,441 |
| UbrelvyUbrogepant | 12 | $25,856 |
| AptiomEslicarbazepine Acetate | 14 | $17,891 |
| Memantine Hcl | 521 | $17,514 |
| Emgality PenGalcanezumab-Gnlm | 15 | $17,414 |
| Nurtec OdtRimegepant Sulfate | 13 | $15,117 |
| Modafinil | 21 | $8,688 |
| Memantine Hcl ErMemantine Hcl | 63 | $8,022 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 243 | $7,047 |
| Carbamazepine ErCarbamazepine | 42 | $6,769 |
| Donepezil Hcl | 630 | $6,222 |
| Levetiracetam | 180 | $5,764 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 81 | $5,636 |
| Lamotrigine OdtLamotrigine | 11 | $4,016 |
| Carbamazepine | 49 | $3,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,321 | $78,44114 claims |
| AbbVieUbrelvy | $1,180 | $25,85612 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $198 | $17,89114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.
Other neurology in Fountain Valley
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.